down arrow

Renovaro, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29350E1047
USD
1.30
0.04 (3.17%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.161.31

52 Week

0.1221.00
Valuation
Technical
Day's Volume

CASH

402.74 k

Shareholding (Mar 2025)

FII

1.14%

Held by 31 FIIs

DII

90.29%

Held by 11 DIIs

Promoter

0.02%

How big is Renovaro, Inc.?

22-Jun-2025

As of Jun 18, Renovaro, Inc. has a market capitalization of 61.88 million and reported net sales of 0.00 million with a net profit of -74.78 million for the latest four quarters. As of Jun 24, shareholder's funds are at 131.98 million and total assets at 163.13 million.

As of Jun 18, Renovaro, Inc. has a market capitalization of 61.88 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -74.78 million.<BR><BR>As of Jun 24, the reporting period shows Shareholder's Funds at 131.98 million and Total Assets at 163.13 million.

Read More

What does Renovaro, Inc. do?

22-Jun-2025

Renovaro, Inc. is a biotechnology company focused on developing vaccines for colorectal cancer and gene therapies for HIV/AIDS, classified as a micro-cap with a market cap of $61.88 million. It currently reports no net sales or profits and has a debt equity ratio of 0.06.

Overview: <BR>Renovaro, Inc. is a biotechnology company focused on developing vaccines for colorectal cancer and gene therapies for HIV/AIDS, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>- Most recent Net Sales: Not available <BR>- Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>- Market-cap: USD 61.88 Million (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: NA (Loss Making) <BR>- Industry P/E: NA <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 0.06 <BR>- Return on Equity: -24.90% <BR>- Price to Book: 0.70 <BR><BR>Contact Details: <BR>- Address: Century City Medical Plaza, 2080 Century City East LOS ANGELES CA : 90067 <BR>- Tel: 1 212 7630184 <BR>- Fax: 1 845 8183588 <BR>- Website: https://enochianbio.com/

Read More

Who are in the management team of Renovaro, Inc.?

22-Jun-2025

As of March 2022, the management team of Renovaro, Inc. includes Mr. Rene Sindlev (Independent Chairman), Dr. Mark Dybul (Executive Vice Chairman and Principal Executive Officer), Mr. Henrik Gronfeldt-Sorensen, Mr. Gregg Alton, Dr. Carol Brosgart, and Ms. Evelyn D'An (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Renovaro, Inc. includes the following individuals:<BR><BR>- Mr. Rene Sindlev, Independent Chairman of the Board<BR>- Dr. Mark Dybul, Executive Vice Chairman of the Board, Principal Executive Officer<BR>- Mr. Henrik Gronfeldt-Sorensen, Director<BR>- Mr. Gregg Alton, Independent Director<BR>- Dr. Carol Brosgart, Independent Director<BR>- Ms. Evelyn D'An, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Renovaro, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Renovaro, Inc. is in a bearish trend with weak strength, indicated by negative signals from moving averages, RSI, and Bollinger Bands, while significantly underperforming the S&P 500 with a year-to-date return of -80.65%.

As of 3 September 2025, the technical trend for Renovaro, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include the daily moving averages and the weekly Dow Theory, both indicating bearish trends. The weekly RSI is also bearish, while the Bollinger Bands show a bearish signal on both weekly and monthly time frames. Despite some mildly bullish signals in the MACD and KST on the weekly, the overall sentiment remains negative. Additionally, Renovaro's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -80.65% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 43 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.06

stock-summary
Return on Equity

-24.90%

stock-summary
Price to Book

0.49

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-41.57%
0%
-41.57%
6 Months
-54.86%
0%
-54.86%
1 Year
-87.5%
0%
-87.5%
2 Years
-96.07%
0%
-96.07%
3 Years
9.24%
0%
9.24%
4 Years
-98.61%
0%
-98.61%
5 Years
-95.5%
0%
-95.5%

Renovaro, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Renovaro, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Renovaro, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include the daily moving averages and the weekly Dow Theory, both indicating bearish trends. The weekly RSI is also bearish, while the Bollinger Bands show a bearish signal on both weekly and monthly time frames. Despite some mildly bullish signals in the MACD and KST on the weekly, the overall sentiment remains negative. Additionally, Renovaro's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -80.65% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-26.02%
EBIT to Interest (avg)
-19.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.77%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.60
EV to EBIT
-2.92
EV to EBITDA
-2.94
EV to Capital Employed
0.62
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-21.33%
ROE (Latest)
-24.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 20 Schemes (8.55%)

Foreign Institutions

Held by 31 Foreign Institutions (1.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 100.34% vs -1,272.09% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-8.70",
          "chgp": "52.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.50",
          "val2": "-49.90",
          "chgp": "109.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.20",
          "val2": "-59.00",
          "chgp": "100.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is -122.67% vs 64.99% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.30",
          "val2": "-19.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.60",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-58.60",
          "val2": "-19.40",
          "chgp": "-202.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.40",
          "val2": "-39.70",
          "chgp": "-122.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.10
-8.70
52.87%
Interest
0.20
0.30
-33.33%
Exceptional Items
4.50
-49.90
109.02%
Consolidate Net Profit
0.20
-59.00
100.34%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 100.34% vs -1,272.09% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.30
-19.50
-40.00%
Interest
1.00
0.60
66.67%
Exceptional Items
-58.60
-19.40
-202.06%
Consolidate Net Profit
-88.40
-39.70
-122.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is -122.67% vs 64.99% in Jun 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Renovaro, Inc. stock-summary
stock-summary
Renovaro, Inc.
Pharmaceuticals & Biotechnology
Enochian Biosciences Inc, formerly DanDrit Biotech USA, Inc., is a Denmark-based biotechnology company. The Company focuses on developing vaccine against colorectal cancer. It has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark). The Company offers MCV platform technology, which is a cellular immunotherapy for treatment of cancer. Also, the Company develops gene therapies for patients with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS).
Company Coordinates stock-summary
Company Details
Century City Medical Plaza, 2080 Century City East LOS ANGELES CA : 90067
stock-summary
Tel: 1 212 7630184
stock-summary
https://enochianbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."